Review: Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers prevent type 2 diabetes: COMMENTARY

Padwal, Raj
May 2006
ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p64
Academic Journal
The article presents comments of the author on a study which found that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers prevent type 2 diabetes. Diabetes incidence may be reduced by renin-angiotensin inhibitors, increased by thiazides and β ;-blockers and largely unchanged by calcium-channel blockers. Evidence is required before renin-angiotensin inhibitors can be definitively considered to prevent diabetes. It is reasonable to prescribe renin-angiotensin inhibitors preferentially in patients at high risk for type 2 diabetes, who already require antihypertensive drug treatment and have no compelling indication for a different agent.


Related Articles

  • Antihypertensive Therapy and Incidence of Type 2 Diabetes in an Elderly Cohort. Padwal, Raj; Mamdani, Muhammad; Alter, David A.; Hux, Jane E.; Rottwell, Deanna M.; Tu, Karen; Laupacis, Andreas // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2458 

    OBJECTIVE -- The aim of this study was to determine whether the incidence of type 2 diabetes differed among elderly users of four major antihypertensive drug classes. RESEARCH DESIGN AND METHODS -- This was a retrospective, observational cohort study of previously untreated elderly patients...

  • Review: Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers prevent type 2 diabetes.  // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p64 

    The article discusses a study which aims to determine whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) reduces risk for type 2 diabetes in patients with hypertension or other cardiovascular risk factors. 12 RCTs met the selection criteria for the...

  • Independent Nurse: Treatment based on beta-blockers could be phased out, trial suggests. Snow, Tamsin; Pownall, Mark // GP: General Practitioner;9/16/2005, p70 

    The article reports on a study which states that the use of beta-blockers as first-line therapy for uncomplicated hypertension is likely to become a thing of the past. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) found that combination treatment with a calcium channel blocker and an ACE...

  • Calcium channel blockers associated with less diabetes. Mayor, Susan // BMJ: British Medical Journal (International Edition);9/9/2006, Vol. 337 Issue 7567, p514 

    The article offers a look at a medical study by the Anglo-Scandinavian cardiac outcomes trial (ASCOT), which found that treatment for high blood pressure based on a calcium blocker may lower the risk of diabetes. According to the author, calcium antagonists such as amlodipine, with or without...

  • No new hypertension guidance until April.  // GP: General Practitioner;10/14/2005, p7 

    The article reports that a joint NICE and British Hypertension Society (BHS) guideline on the management of hypertension will not be produced for another six months. NICE and the BHS had said they would revise existing guidelines which give conflicting advice over the best treatment for...

  • Managing blood pressure and lipids in diabetes in primary care. Inglis, Andrew // Practice Nursing;Feb2012, Vol. 23 Issue 2, p82 

    The article discusses the administration of blood pressure and lipids for type 2 diabetes in primary care. It also tackles the treatment for patients with type 1 diabetes. The recommendation of the National Institute for Health and Clinical Excellence (NICE) in Great Britain on blood pressure...

  • Use CCBs with Caution in Blacks with Diabetic Nephropathy.  // Kidney;Jan/Feb98, Vol. 7 Issue 1, p18 

    Investigates the contrasting effects of calcium channel blockade versus angiotensin converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. Effects of isradapine on the course of nephropathy as compared with those of...

  • Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. RUGGENENTI, PIERO; MOSCONI, LIDIA; SANGALLI, FABIO; CASIRAGHI, FEDERICA; GAMBARA, VINCENZO; REMUZZI, GIUSEPPE; REMUZZI, ANDREA; Remuzzi, Andrea // Kidney International;Mar1999, Vol. 55 Issue 3, p984 

    Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Background. In patients with insulin-dependent diabetes mellitus (IDDM) and overt nephropathy glomerular barrier size-selectivity progressively deteriorates with time and is...

  • Statin, Calcium Channel Blocker and Beta Blocker Therapy May Decrease the Incidence of Tuberculosis Infection in Elderly Taiwanese Patients with Type 2 Diabetes. Mei-Yueh Lee; Kun-Der Lin; Wei-Hao Hsu; Hsiu-Ling Chang; Yi-Hsin Yang; Pi-Jung Hsiao; Shyi-Jang Shin // International Journal of Molecular Sciences;2015, Vol. 16 Issue 5, p11369 

    Background: It is well known that diabetes mellitus impairs immunity and therefore is an independent risk factor for tuberculosis. However, the influence of associated metabolic factors, such as hypertension, dyslipidemia and gout has yet to be confirmed. This study aimed to investigate whether...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics